CN103338786A - 用于治疗淀粉样斑块相关症状的组合物和方法 - Google Patents

用于治疗淀粉样斑块相关症状的组合物和方法 Download PDF

Info

Publication number
CN103338786A
CN103338786A CN2011800667946A CN201180066794A CN103338786A CN 103338786 A CN103338786 A CN 103338786A CN 2011800667946 A CN2011800667946 A CN 2011800667946A CN 201180066794 A CN201180066794 A CN 201180066794A CN 103338786 A CN103338786 A CN 103338786A
Authority
CN
China
Prior art keywords
seq
antibody
apoe
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800667946A
Other languages
English (en)
Chinese (zh)
Inventor
D.霍尔兹曼
J.金
H.江
A.艾尔托莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of CN103338786A publication Critical patent/CN103338786A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN2011800667946A 2010-12-02 2011-12-02 用于治疗淀粉样斑块相关症状的组合物和方法 Pending CN103338786A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US61/419,060 2010-12-02
US201161548542P 2011-10-18 2011-10-18
US61/548,542 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (1)

Publication Number Publication Date
CN103338786A true CN103338786A (zh) 2013-10-02

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800667946A Pending CN103338786A (zh) 2010-12-02 2011-12-02 用于治疗淀粉样斑块相关症状的组合物和方法

Country Status (14)

Country Link
US (2) US20140037638A1 (enExample)
EP (1) EP2646053A4 (enExample)
JP (1) JP2014502276A (enExample)
KR (1) KR20140017513A (enExample)
CN (1) CN103338786A (enExample)
AU (1) AU2011336360A1 (enExample)
BR (1) BR112013013723A2 (enExample)
CA (1) CA2819679A1 (enExample)
MX (1) MX2013006116A (enExample)
NZ (1) NZ611614A (enExample)
RU (1) RU2013130002A (enExample)
SG (1) SG190952A1 (enExample)
WO (1) WO2012075422A2 (enExample)
ZA (1) ZA201303996B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013168174A1 (en) * 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
EP3452074A4 (en) * 2016-05-03 2019-12-11 University of South Florida COMPOSITIONS AND METHOD FOR MODULATING THE ABETA PROTEIN
US11124562B2 (en) 2016-10-28 2021-09-21 Washington University Anti-ApoE antibodies
CA3070100A1 (en) * 2017-07-17 2019-01-24 Janssen Biotech, Inc. Antigen binding regions against fibronectin type iii domains and methods of using the same
CN120098122A (zh) * 2019-05-28 2025-06-06 总医院公司 Apoe抗体、融合蛋白及其用途
WO2023069892A1 (en) * 2021-10-19 2023-04-27 Short Jay M Conditionally active proteins for neurodegenerative diseases
AU2023399623A1 (en) * 2022-11-30 2025-07-03 Bio-Techne Corporation Natural killer cell engagers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1092525A (zh) * 1992-10-13 1994-09-21 杜克大学 早老性痴呆的检测方法
CN1890266A (zh) * 2003-11-28 2007-01-03 阿斯特拉曾尼卡有限公司 抗体
WO2007098417A2 (en) * 2006-02-21 2007-08-30 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
WO2011109246A1 (en) * 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005228764A1 (en) * 2004-03-30 2005-10-13 Renomedix Institute Inc. Remedy for prion disease and method of producing the same
AU2007332473B2 (en) * 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1092525A (zh) * 1992-10-13 1994-09-21 杜克大学 早老性痴呆的检测方法
CN1890266A (zh) * 2003-11-28 2007-01-03 阿斯特拉曾尼卡有限公司 抗体
WO2007098417A2 (en) * 2006-02-21 2007-08-30 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
WO2011109246A1 (en) * 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张芃等: "ApoE抗体阻断ApoE/Aβ1-42结合并减少Aβ1-42聚集、纤维化作用的研究", 《中国神经免疫学和神经病学杂志》 *

Also Published As

Publication number Publication date
US20160355581A1 (en) 2016-12-08
US20140037638A1 (en) 2014-02-06
WO2012075422A2 (en) 2012-06-07
JP2014502276A (ja) 2014-01-30
WO2012075422A3 (en) 2012-10-04
ZA201303996B (en) 2015-10-28
EP2646053A4 (en) 2014-05-28
NZ611614A (en) 2015-07-31
KR20140017513A (ko) 2014-02-11
EP2646053A2 (en) 2013-10-09
CA2819679A1 (en) 2012-06-07
SG190952A1 (en) 2013-07-31
MX2013006116A (es) 2013-10-17
BR112013013723A2 (pt) 2019-09-24
RU2013130002A (ru) 2015-01-10
AU2011336360A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
US20160355581A1 (en) Compositions and methods for treating amyloid plaque associated symptoms
AU2006319358B2 (en) Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US7122374B1 (en) Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
KR100701580B1 (ko) 항-아밀로이드 항체를 이용한 아밀로이드 제거 방법들
US20230416393A1 (en) Cd6 antibody for treatment of t-cell mediated diseases or disorders
US11926660B2 (en) Anti-ApoE antibodies
JP2001511369A (ja) 病理的状態に関連する斑および凝集物の蛋白成分の選択的な溶解用のプロテアーゼ活性を有する触媒性モノクローナル抗体
US20100322932A1 (en) Methods for amyloid removal using anti-amyloid antibodies
EP2195025B1 (en) Therapeutic antibody purification method and method of use
CN111164105B (zh) 抗pacap抗体
US8075893B2 (en) Pharmaceutical composition of F(ab′)2 antibody fragments and a process for the preparation thereof
CN117919419A (zh) 末梢神经病变或伴随确认到末梢神经病变或星形胶质细胞病变的疾病的疼痛的预防或治疗剂
US20200385461A1 (en) Fusion constructs and uses thereof
AU2003262458B2 (en) Methods for amyloid removal using anti-amyloid antibodies
WO2025119350A1 (zh) 靶向Tau的特异性结合蛋白及其应用
AU2012201856A1 (en) Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20170524

AD01 Patent right deemed abandoned